Early Improvement with Vortioxetine Predicts Response and Remission: A Post Hoc Analysis of Data from a Clinical Trial Conducted in Japan.

Takeshi Inoue Shinji FujimotoTatsuro MarumotoTadayuki KitagawaKazuyuki IshidaTadashi NakajimaYoshiya MoriguchiKeita FujikawaKoichiro Watanabe

Published in: Neuropsychiatric disease and treatment (2021)

Improvement with vortioxetine may be predicted by early partial improvement in MADRS score. Some patients may benefit from longer-term treatment even without early improvement, another finding that may aid clinical decision-making. ClinicalTrials.gov registration for primary study: NCT02389816.

Keyphrases

clinical trial
end stage renal disease
major depressive disorder
decision making
ejection fraction
chronic kidney disease
randomized controlled trial
electronic health record
machine learning
rheumatoid arthritis
bipolar disorder
open label
patient reported outcomes
combination therapy